ClinicalTrials.gg
CompletedNCT02874846Updated Apr 17, 2018Results posted

Nocturnal/Diurnal Intraocular Pressure-Lowering Effect of Netarsudil Ophthalmic Solution

A Phase 2 interventional study of Netarsudil ophthalmic solution 0.02% and Netarsudil Ophthalmic Solution Vehicle in Ocular Hypertension and Open Angle Glaucoma, sponsored by Aerie Pharmaceuticals. Completed at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-04-17.

Primary conditionGlaucoma, Open-AngleRegistry: Ocular HypertensionReclassifiedWhy we changed it
Registry
Ocular Hypertension — the first condition term the registry derived for this study.
ClinicalTrials.gg
Glaucoma, Open-Angle
Why
  1. The study's listed conditions name Glaucoma, Open-Angle, a narrower term within Ocular Hypertension.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Aerie Pharmaceuticals (part of Alcon) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies testing netarsudil in Glaucoma, Open-Angle — 3 open to participants now, 4 under way, none of them phase 3. netarsudil · Glaucoma, Open-Angle.

Enrollment
16th of 17
12 · median 85
Started
2016
the only one that year
Phase 2
6 of 17
none open now
Registered
6th of 17
by date
Lead sponsor
11 of 17
Aerie Pharmaceuticals

Among the 17 studies testing netarsudil in Glaucoma, Open-Angle, this one is the 16th largest by enrollment, is the only one that started in 2016, is one of 6 in phase 2, and was the 6th registered.

Glaucoma, Open-Angle

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

Browse Glaucoma, Open-Angle studies →

Open to participants now

3 of the 17 studies testing netarsudil in Glaucoma, Open-Angle are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Where they have run

About netarsudil

netarsudil: first FDA approval 2017 (RHOPRESSA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 82 Glaucoma, Open-Angle studies recruiting now, 63 (77%) set no upper age limit and 5 (6%) stop at 75 or younger; 5 take children under 18; 11 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies testing netarsudil in Glaucoma, Open-Angle, or all of them as a file.
02

Study summary

To evaluate effect of Netarsudil Ophthalmic Solution 0.02% on Nocturnal and Diurnal Intraocular Pressure.

03

Conditions studied

  • Ocular Hypertension
  • Open Angle Glaucoma

Browse trials for

04

In context

Glaucoma, Open-Angle Reclassified

924 studies on the registry are indexed under Glaucoma, Open-Angle; 115 are open to participants now.

This study's enrollment of 12 is below the median of 80 across 692 interventional studies indexed under Glaucoma, Open-Angle.

Browse Glaucoma, Open-Angle studies →

Lead sponsor

Aerie Pharmaceuticals is the lead sponsor of 36 studies on the registry; none are open to participants now.

Of its 18 completed or terminated interventional studies of FDA-regulated products, 16 (89%) have results posted.

First submitted before Aerie Pharmaceuticals became part of Alcon.

Compared within Glaucoma, Open-Angle, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Ocular Hypertension. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. 18 years of age or older.
  2. Ocular hypertension or open-angle glaucoma in both eyes.
  3. Unmedicated intraocular pressure > 17 mmHg in one or both eyes and \< 30 mmHg in both eyes.
  4. Corrected visual acuity in each eye equivalent to 20/200 or better.
  5. Able and willing to give signed and follow study instructions.

Exclusion criteria

Exclusion Criteria:

  1. Glaucoma with pseudoexfoliation or pigment dispersion component, history of angle closure, narrow angles.
  2. Intraocular pressure ≥ 30 mmHg.
  3. Use of ocular medications within 30 days.
  4. Known to any component of the test formulations or to medications used routinely during a clinical eye examination.
  5. Previous eye surgery (other than cataract).
  6. Ocular trauma within 6 months.
  7. ocular disease that might interfere with the study.
  8. Central corneal thickness greater than 620 µm.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

06

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Experimental
    Netarsudil Ophthalmic Solution 0.02%

    1 drop in each eye (OU) daily

    Drug: Netarsudil ophthalmic solution 0.02%

  • Placebo comparator
    Netarsudil Ophthalmic Solution Vehicle

    1 drop in each eye (OU) daily

    Other: Netarsudil Ophthalmic Solution Vehicle

Interventions

  • Once daily in both eyes (OU) in the evening (PM) for 7 days

    Also known as: AR-13324

  • OtherNetarsudil Ophthalmic Solution Vehicle

    Once daily in both eyes (OU) in the evening (PM) for 7 days

07

What researchers measure

Primary outcomes

  1. Change in Intraocular Pressure (IOP) Over Nocturnal Time Period

    The primary efficacy endpoint was the mean change from baseline in mean nocturnal IOP (defined as the mean of the 4 nocturnal time points: 21:00, 00:00, 03:00, and 06:00 hours) on Day 8/Day 9

    Time frame: Assessed over 24 hours at 9 pm, midnight, 3 am and 6 am on days 1/2 and 8/9

Secondary outcomes

  1. Number of Participants With Adverse Events as a Measure of Safety and Tolerability

    Time frame: 7 days (day 1/2 to day 8/9)

08

Results

Posted Apr 17, 2018

Participant flow

Participant flow — Overall Study
MilestoneNetarsudil Ophthalmic Solution 0.02%Netarsudil Ophthalmic Solution Vehicle
Started84
Completed84
Not completed00

Outcome measures

PrimaryChange in Intraocular Pressure (IOP) Over Nocturnal Time Period

The primary efficacy endpoint was the mean change from baseline in mean nocturnal IOP (defined as the mean of the 4 nocturnal time points: 21:00, 00:00, 03:00, and 06:00 hours) on Day 8/Day 9

Time frame:
Assessed over 24 hours at 9 pm, midnight, 3 am and 6 am on days 1/2 and 8/9
Reported as:
Mean · mmHg
Change in Intraocular Pressure (IOP) Over Nocturnal Time Period
mmHgNetarsudil Ophthalmic Solution 0.02%Netarsudil Ophthalmic Solution Vehicle
Baseline (Day 1/2); nocturnal mean22.84 ± 2.2123.56 ± 1.94
Visit 4 (Day 8/9); nocturnal mean19.38 ± 2.8623.19 ± 1.95
SecondaryNumber of Participants With Adverse Events as a Measure of Safety and Tolerability
Time frame:
7 days (day 1/2 to day 8/9)
Reported as:
Count of participants · Participants
Number of Participants With Adverse Events as a Measure of Safety and Tolerability
ParticipantsNetarsudil Ophthalmic Solution 0.02%Netarsudil Ophthalmic Solution Vehicle
Number of Participants With Adverse Events as a Measure of Safety and Tolerability00

Adverse events

Collected over Adverse event data was collected over 7 days from day 1/2 to day 8/9.. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Netarsudil Ophthalmic Solution 0.02%0/8 (0%)0/8 (0%)0/8 (0%)
Netarsudil Ophthalmic Solution Vehicle0/4 (0%)0/4 (0%)0/4 (0%)

Baseline characteristics

ITT

Age, Continuous
Age, Continuous(years)Netarsudil Ophthalmic Solution 0.02%Netarsudil Ophthalmic Solution VehicleTotal
Mean64.4 ± 10.2364.5 ± 5.0764.4 ± 8.58
Sex: Female, Male
Sex: Female, Male(Participants)Netarsudil Ophthalmic Solution 0.02%Netarsudil Ophthalmic Solution VehicleTotal
Female426
Male426
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Netarsudil Ophthalmic Solution 0.02%Netarsudil Ophthalmic Solution VehicleTotal
Hispanic or Latino112
Not Hispanic or Latino7310
Unknown or Not Reported000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Netarsudil Ophthalmic Solution 0.02%Netarsudil Ophthalmic Solution VehicleTotal
American Indian or Alaska Native000
Asian000
Native Hawaiian or Other Pacific Islander000
Black or African American639
White213
More than one race000
Unknown or Not Reported000
09

Study locations

1 site
  • Nancy Ramirez
    Bedminster, New Jersey 07921, United States
10

References and documents

Publications

  • Peace JH, McKee HJ, Kopczynski CC. A Randomized, Phase 2 Study of 24-h Efficacy and Tolerability of Netarsudil in Ocular Hypertension and Open-Angle Glaucoma. Ophthalmol Ther. 2021 Mar;10(1):89-100. doi: 10.1007/s40123-020-00322-1. Epub 2020 Nov 26. PubMed 33244711 ↗

Individual participant data

Plan to share: No

11

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Jul 2016, a primary completion of Sep 2016 and a completion of Sep 2016. It does not say whether these dates are actual or estimated.

Results were first posted in Apr 2018, 1 year 7 months after primary completion. A results delay was requested in Sep 2016.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 15, 2016
First posted
Aug 22, 2016
Start
Jul 2016
Primary completionActual
Sep 2016
CompletionActual
Sep 2016
Results delay requested
Sep 27, 2016
Results first posted
Apr 17, 2018
Last update
Apr 17, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 17, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
12

Registry details

Key details

Study ID
NCT02874846
Responsible party
Sponsor
First posted
Aug 22, 2016
Start date
Jul 2016
Primary completion
Sep 2016
Completion
Sep 2016
Results posted
Apr 17, 2018
Last update
Apr 17, 2018

Study contacts

Theresa Heah, MD
study director · Aerie Pharmaceuticals

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Netarsudil

Start the discussion